LymPro Test® is going to be used two fold.
Pharma Service Product PipeLine (slide 5)
and
CLIA Diagnostics Pipeline (slide 25)
Usage of The LymPro Test® will get CLIA in house now & ready for the DIagnostics market in 2017
LymPro Test® is ready & available now as an IUO on the Pharma Service Side
When speaking of the $1.5 Million in revenue, it's important to note that that is not a stagnant or fixed revenue number on the Pharma Side alone.
Slide37
2015 Pharma Services revenue of $1.5M expected to grow significant
Theralink® in breast cancer to expand into other indications
LymPro Test® to add significant potential to pharma services revenue potential
Leader in cell cycle biology
Slide 24
addresses the "possible" use for Pharma.
Slide 5
As for 1.5 million revenue 2015, that was for the TheraLink®Assays, in regards to Breast & Colorectal(CRC) Stage IV Cancers Alone
Slide 21
You can see what they will be introducing this year and beyond. 2016, 2017 etc...
This year 2016 they plan to broaden its usage to
Ovarian (Stage IV*)
Pancreatic (Stage IV*)
NSCLC (Stage IV*)
CRC (Stage I – III)
Breast (Stage III)
Slide 23
They are forecasting 20% growth on Theralink® alone
Now
Under the CLIA Diagnostics Pipeline
Slide 37
Introducing proprietary diagnostic tests into market in 2017
Ovarian cancer: OvaDx® Market potential of $2B+ (replacing CA-125)
Multiple Sclerosis: MSPrecise® Market potential of $200M+ (improving Tx intervention)
Alzheimer’s disease: LymPro Test® Market potential of $3B+ (65yr Medicare screen)
So one needs to look at this deal in a few different ways, most importantly how and where they are expecting revenue to come from.
The Combined Companies Business Model
The combined company will offer cutting edge pharma services in the areas of cell cycle biology and signal transduction pathways to assist pharmaceutical companies and medical researchers in identifying treatment pathways for disease.
The combined company will leverage its CLIA/CAP laboratory infrastructure to launch proprietary diagnostic tests in the areas of Ovarian Cancer, Multiple Sclerosis and Alzheimer’s disease, and related non- proprietary assays.
http://content.stockpr.com/amarantus/db/184/1...+FINAL.pdf
Of course these are all "goals" and the argument can be, well we'll see if the 3 way deal even pans out...and or if they will be able to sell any of these tests.
And yes, we will see if it does or doesn't or they can or they can't soon enough.
As for the
ESS Severe Adult Burns ODD Trial
ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army
The 10-patient trial will be conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas
Pau Hana!
Cheers
Pharma Service Product PipeLine (slide 5)
and
CLIA Diagnostics Pipeline (slide 25)
Usage of The LymPro Test® will get CLIA in house now & ready for the DIagnostics market in 2017
LymPro Test® is ready & available now as an IUO on the Pharma Service Side
When speaking of the $1.5 Million in revenue, it's important to note that that is not a stagnant or fixed revenue number on the Pharma Side alone.
Slide37
2015 Pharma Services revenue of $1.5M expected to grow significant
Theralink® in breast cancer to expand into other indications
LymPro Test® to add significant potential to pharma services revenue potential
Leader in cell cycle biology
Slide 24
addresses the "possible" use for Pharma.
Slide 5
As for 1.5 million revenue 2015, that was for the TheraLink®Assays, in regards to Breast & Colorectal(CRC) Stage IV Cancers Alone
Slide 21
You can see what they will be introducing this year and beyond. 2016, 2017 etc...
This year 2016 they plan to broaden its usage to
Ovarian (Stage IV*)
Pancreatic (Stage IV*)
NSCLC (Stage IV*)
CRC (Stage I – III)
Breast (Stage III)
Slide 23
They are forecasting 20% growth on Theralink® alone
Now
Under the CLIA Diagnostics Pipeline
Slide 37
Introducing proprietary diagnostic tests into market in 2017
Ovarian cancer: OvaDx® Market potential of $2B+ (replacing CA-125)
Multiple Sclerosis: MSPrecise® Market potential of $200M+ (improving Tx intervention)
Alzheimer’s disease: LymPro Test® Market potential of $3B+ (65yr Medicare screen)
So one needs to look at this deal in a few different ways, most importantly how and where they are expecting revenue to come from.
The Combined Companies Business Model
The combined company will offer cutting edge pharma services in the areas of cell cycle biology and signal transduction pathways to assist pharmaceutical companies and medical researchers in identifying treatment pathways for disease.
The combined company will leverage its CLIA/CAP laboratory infrastructure to launch proprietary diagnostic tests in the areas of Ovarian Cancer, Multiple Sclerosis and Alzheimer’s disease, and related non- proprietary assays.
http://content.stockpr.com/amarantus/db/184/1...+FINAL.pdf
Of course these are all "goals" and the argument can be, well we'll see if the 3 way deal even pans out...and or if they will be able to sell any of these tests.
And yes, we will see if it does or doesn't or they can or they can't soon enough.
As for the
ESS Severe Adult Burns ODD Trial
ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army
The 10-patient trial will be conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas
Pau Hana!
Cheers
5
1
